PDT Partners’s OptimizeRx OPRX Stock Holding History

PDT Partners’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,269	Closed	-$264K	–	873
2021 Q2	$264K	Buy	+4,269	New	+$217K	0.02%	646

Other funds holding OPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PDT Partners's OPRX Position: Q3 2021 in Review

PDT Partners sold out of OptimizeRx (OPRX) in Q3 2021, closing a stake of 4,269 shares — an estimated $264K sold.

PDT Partners first reported a position in OPRX in Q2 2021 and held it in 1 quarter. The position peaked at $264K in Q2 2021. 163 funds tracked by Wall St. Rank hold OPRX as of Q3 2021.

PDT Partners reported no remaining OptimizeRx position as of Q3 2021 after selling out during the quarter.
PDT Partners sold 4,269 OptimizeRx shares in Q3 2021, an estimated $264K.
PDT Partners first reported a position in OptimizeRx in Q2 2021 and held it in 1 quarter.
PDT Partners's OptimizeRx position peaked at $264K in Q2 2021.
163 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.